Literature DB >> 8562155

Analysis of P-glycoprotein expression in osteosarcoma.

M Serra1, K Scotlandi, M C Manara, D Maurici, S Benini, M Sarti, M Campanacci, N Baldini.   

Abstract

Current treatment of high-grade osteosarcoma combines surgical removal of the lesion with chemotherapy. In this study we evaluated whether the expression of P-glycoprotein, a protein closely associated with multidrug resistance, may be helpful in identifying the patients whose tumours will be further resistant to specific agents. By using multidrug-resistant osteosarcoma cell lines as standards, the expression of P-glycoprotein was evaluated in 105 cases of primary and metastatic osteosarcoma by semiquantitative immunofluorescence. Overexpression of the protein was shown in 23% of primary and in 50% of metastatic lesions. In 38 cases, homogeneously treated and followed-up for at least 24 months, overexpression of P-glycoprotein appeared to be associated with a higher relapse rate and with a trend toward a worse outcome. These data support the role of P-glycoprotein in the response to chemotherapy and its involvement in the determination of the outcome of osteosarcoma patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8562155     DOI: 10.1016/0959-8049(95)00335-5

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  10 in total

1.  P-glycoprotein expression in soft-tissue sarcomas.

Authors:  H Nakanishi; A Myoui; T Ochi; K Aozasa
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

2.  Cluster of differentiation 147 mediates chemoresistance in breast cancer by affecting vacuolar H+-ATPase expression and activity.

Authors:  Yehong Kuang; Shouman Wang; Lili Tang; Jian Hai; Guojiao Yan; Liqiu Liao
Journal:  Oncol Lett       Date:  2018-03-07       Impact factor: 2.967

3.  A new mdr-1 encoded P-170 specific monoclonal antibody: (6/1C) on paraffin wax embedded tissue without pretreatment of sections.

Authors:  E Moran; A Larkin; G Doherty; P Kelehan; S Kennedy; M Clynes
Journal:  J Clin Pathol       Date:  1997-06       Impact factor: 3.411

4.  Evaluation of P-glycoprotein expression in soft tissue sarcomas of the extremities.

Authors:  M Serra; K Scotlandi; M C Manara; D Maurici; S Benini; M Sarti; G Nini; G Barbanti-Brodano; N Baldini
Journal:  Cytotechnology       Date:  1996       Impact factor: 2.058

5.  Osteoblastic differentiation and P-glycoprotein multidrug resistance in a murine osteosarcoma model.

Authors:  H Takeshita; K Kusuzaki; H Murata; T Suginoshita; M Hirata; S Hashiguchi; T Ashihara; M C Gebhardt; H J Mankin; Y Hirasawa
Journal:  Br J Cancer       Date:  2000-04       Impact factor: 7.640

6.  Is (99m)Tc-MIBI scintigraphy a predictor of response to pre-operative neoadjuvant chemotherapy in Osteosarcoma?

Authors:  Mohammad Gharehdaghi; Vahid Reza Dabbagh Kakhki; Alireza Khooei; Gholamhosein Novferesti; Alireza Hootkani; Mahdi Farzadnia; Ramin Sadeghi
Journal:  Asia Ocean J Nucl Med Biol       Date:  2013

7.  Immunohistochemical Estimates of Angiogenesis, Proliferative Activity, p53 Expression, and Multiple Drug Resistance Have No Prognostic Impact in Osteosarcoma: A Comparative Clinicopathological Investigation.

Authors:  Flemming Brandt Sorensen; Kenneth Jensen; Michael Vaeth; Henrik Hager; Anette Mariane Daa Funder; Akmal Safwat; Johnny Keller; Mariann Christensen
Journal:  Sarcoma       Date:  2009-02-25

8.  High-dose cyclosporin with etoposide--toxicity and pharmacokinetic interaction in children with solid tumours.

Authors:  G Bisogno; F Cowie; A Boddy; H D Thomas; G Dick; C R Pinkerton
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

Review 9.  Understanding the Biology of Bone Sarcoma from Early Initiating Events through Late Events in Metastasis and Disease Progression.

Authors:  Limin Zhu; Madonna M McManus; Dennis P M Hughes
Journal:  Front Oncol       Date:  2013-09-17       Impact factor: 6.244

10.  Altered pH gradient at the plasma membrane of osteosarcoma cells is a key mechanism of drug resistance.

Authors:  Sofia Avnet; Silvia Lemma; Margherita Cortini; Paola Pellegrini; Francesca Perut; Nicoletta Zini; Katsuyuki Kusuzaki; Tokuhiro Chano; Giulia Grisendi; Massimo Dominici; Angelo De Milito; Nicola Baldini
Journal:  Oncotarget       Date:  2016-09-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.